// STATE LEGISLATION TRACKER

California SB 41: Pharmacy benefits.

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Signed

State: California
Bill: SB 41
Filed: 2024-12-03
Read the bill: OpenStates →
Last reviewed: 2026-10-02

Plain-English Summary

California SB 41 regulates pharmacy benefit managers to reduce prescription drug pricing practices like spread pricing and rebate retention. It does not appear to directly change compounded peptide access, off-label prescribing, telehealth rules, NP or naturopath scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

Main impact is on pharmacy benefit managers, not peptide prescribing rules
Could modestly affect insured prescription costs if a peptide drug is covered
Cash-pay compounded peptides are unlikely to be directly affected
No clear change to telehealth prescribing or clinician scope
No apparent new controlled-substance or PDMP rule

What to Watch For

✓

Opportunity If PBM reforms lower covered drug costs, patients using insured peptide-related prescriptions may benefit.

Note Compounded peptide access likely remains governed by existing pharmacy, FDA, and prescriber rules.

Concern Coverage or formulary effects could still matter for patients using FDA-approved peptide drugs.

Where the Bill Stands

SB 41 was signed by the Governor and chaptered as California law in October 2025.

· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws